We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Assertio (ASRT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Assertio is one of 1186 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 85% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ASRT has returned 20.6% so far this year. Meanwhile, the Medical sector has returned an average of -15.5% on a year-to-date basis. This shows that Assertio is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Sensus Healthcare, Inc. (SRTS - Free Report) . The stock has returned 18% year-to-date.
In Sensus Healthcare, Inc.'s case, the consensus EPS estimate for the current year increased 162.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, a group that includes 231 individual stocks and currently sits at #151 in the Zacks Industry Rank. This group has lost an average of 27.9% so far this year, so ASRT is performing better in this area.
Sensus Healthcare, Inc. however, belongs to the Medical - Instruments industry. Currently, this 105-stock industry is ranked #202. The industry has moved -30.7% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Assertio and Sensus Healthcare, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Assertio (ASRT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Assertio is one of 1186 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 85% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ASRT has returned 20.6% so far this year. Meanwhile, the Medical sector has returned an average of -15.5% on a year-to-date basis. This shows that Assertio is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Sensus Healthcare, Inc. (SRTS - Free Report) . The stock has returned 18% year-to-date.
In Sensus Healthcare, Inc.'s case, the consensus EPS estimate for the current year increased 162.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, a group that includes 231 individual stocks and currently sits at #151 in the Zacks Industry Rank. This group has lost an average of 27.9% so far this year, so ASRT is performing better in this area.
Sensus Healthcare, Inc. however, belongs to the Medical - Instruments industry. Currently, this 105-stock industry is ranked #202. The industry has moved -30.7% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Assertio and Sensus Healthcare, Inc. as they could maintain their solid performance.